Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

10 treatments under study, led by Pirarubicin

Research Leaders

7 sponsors active, led by Korea Cancer Center Hospital

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1/2 (1)
Phase 2 (1)
Phase 4 (1)

Trial Status

Unknown2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT02533700Phase 2Unknown

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

NCT01746992Phase 4Unknown

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

NCT01198665Phase 1/2Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

Showing all 3 trials

Research Network

Common Treatments

  • Pirarubicin1
  • Ifosfamide1
  • Doxorubicin1
  • Etoposide Phosphate1
  • Methotrexate1

Active Sponsors

  • Korea Cancer Center Hospital1
  • Yonsei University1
  • Asan Medical Center1
  • Shandong Provincial Hospital1
  • Ruijin Hospital1

Top Investigators

Related Conditions

  • Enteropathy Associated T Cell Lymphoma2
  • Subcutaneous Panniculitis Like T Cell Lymphoma2
  • Alknegative Anaplastic Large Cell Lymphoma2
  • Peripheral Tcell Lymphoma Not Otherwise Specified1
  • Hepatosplenic Tcell Lymphoma1

Activity Timeline